StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Oncology Biosimilars Portfolio by Year

Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Oncology Biosimilars Portfolio: $1,301M in FY2025, up 25.5% from a year earlier.

Latest, FY2025
1,301
Period ended Dec 31, 2025
Change on a year earlier
+25.5%
1,037 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Oncology biosimilars (g) | 1,301 | 1,037 | 25% | 26% | 914 | 628 | 46% | 387 | 409 | (5%) | (5%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,301+25.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20241,037-26.3%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20231,407-19.7%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20221,753–Form 10-K (filed 2025-02-27) ↗

Breakdown

What makes up oncology Biosimilars Portfolio

Cite this data

StockData. (2026). Pfizer Oncology Biosimilars Portfolio ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/onc-biosim-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.